# HEROEX-1 (NCT06521554)

> A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06521554
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Nuvalent Inc.
- Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor
- Interventions: NVL-330
- Enrollment: 200
- Primary outcome: Recommended Phase 2 Dose (RP2D)
- Primary outcome: Maximum Tolerated Dose (MTD)
- Primary outcome: Incidence and severity of Treatment Emergent Adverse Events (TEAEs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=heroex-1-nct06521554